Welcome to our dedicated page for VISKASE HOLDINGS SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viskase Holdings, Inc. (ENZN) filings document the issuer's completed transition from Enzon Pharmaceuticals, Inc. to Viskase Holdings, including material-event reports on the merger closing, name change, exchange offer for Series C Non-Convertible Redeemable Preferred Stock, and related capital-structure disclosures.
The company's 8-K records also cover governance and ownership matters, including a Section 382 Rights Agreement, changes in certifying accountant, officer appointments, and amendments to the credit agreement of Viskase Companies, LLC, a wholly owned subsidiary. Other recurring disclosure areas include shareholder voting matters, material agreements, operating and financial results, risk factors, and legacy clinical or regulatory disclosures.
Enzon Pharmaceuticals amended its merger agreement with Viskase Companies and the related support agreement with Icahn Enterprises Holdings (IEH). The updates reflect recent developments at Viskase and expected near‑term operations. A Special Committee of independent directors at both companies recommended the amendments, and each board approved them.
Under the amended IEH support agreement, IEH will deliver written consents for all Enzon common shares it holds to approve the merger and a charter amendment. IEH will also exchange all Series C Preferred Stock into Enzon common stock before closing, based on the full liquidation preference and the 20‑Day VWAP.
Enzon plans to file a Form S‑4 including a consent solicitation statement to seek shareholder approval for the amended merger terms, a name change to Viskase Holdings, Inc., and a Reverse Stock Split. The combined company’s board is anticipated to include Jordan Bleznick, Randolph C. Read, and additional directors designated by Viskase. Enzon believes its net operating losses and other tax benefits will be maintained and available to the combined company following the merger.
Enzon Pharmaceuticals, Inc. has amended its Section 382 Rights Agreement again to adjust the length of its shareholder rights plan. On September 30, 2025, the company entered into a Fifth Amendment that changes the Final Expiration Date of the rights from the close of business on September 30, 2025 to the close of business on December 31, 2025. This plan is designed under Section 382 of the tax code, which typically relates to preserving tax attributes such as net operating losses by discouraging certain changes in ownership.
The company notes that, aside from extending the Final Expiration Date, the terms of the Rights Agreement remain unchanged. Management states that it believes setting a Final Expiration Date of December 31, 2025 is in the best interests of the company and its stockholders. Prior amendments had repeatedly adjusted the expiration date over the last several years, and all versions of the agreement and amendments are incorporated by reference as exhibits.